GLPG
$33.25
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T produ...
Recent News
Assessing Galapagos (ENXTAM:GLPG) Valuation After Mixed Returns And A Modest Undervaluation Estimate
Galapagos stock: recent performance snapshot Galapagos (ENXTAM:GLPG) has delivered a mixed return profile, with a 1 day decline of 2.29%, a slightly negative week, and a month pullback, while the past 3 months and year show positive total returns. Over a longer horizon, the stock reflects pressure, with 3 year and 5 year total returns in negative territory. This matters for anyone weighing shorter term price moves against the company’s multi year track record. See our latest analysis for...
Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ...
Galapagos NV (GLPG) reports a significant turnaround with an operating profit of EUR295.1 million, while navigating strategic reorganization and leveraging its partnership with Gilead.
Galapagos Q4 Earnings Call Highlights
Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell therapy activities. Management emphasized that the company ended 2025 with roughly €3 billion in cash,
Galapagos Adds Clinical Expert To Board As Pipeline Strategy Evolves
Galapagos NV (ENXTAM:GLPG) has appointed Dr. Paulo Fontoura as a Non Executive Independent Director to its Board. Dr. Fontoura brings clinical development and operational experience from previous senior roles at large pharmaceutical companies. The appointment signals added focus on advancing therapies across multiple therapeutic areas. For you as an investor following ENXTAM:GLPG, this Board change is worth watching because it touches directly on how the company thinks about drug...
Galapagos (ENXTAM:GLPG) Valuation Check After Mixed Results And Ongoing Net Loss
Galapagos (ENXTAM:GLPG) has been drawing attention after a mixed set of fundamentals, with revenue of €286.921m alongside a net loss of €443.873m. This has prompted investors to reconsider how they view this biotech stock today. See our latest analysis for Galapagos. At a share price of €28.36, Galapagos has seen a modest 2.68% 1 month share price return, while the 1 year total shareholder return of 13.17% contrasts with a 35.34% total shareholder return decline over three years. This...